Boniva generic
Boniva is an osteoporosis drug owned by Hoffmann La Roche. Its active ingredient is ibandronate sodium. Boniva was first authorised for market use on 16 May, 2003.
When will Boniva generic be available?
The generic version of Boniva is expected to be released after 06 May, 2023, following the expiration of its last patent.
Boniva uses
Boniva is used for the treatment and prevention of osteoporosis in postmenopausal women. It does this through the once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid.
Boniva patent expiration
Boniva has a total of 3 drug patents, all of which have expired. The last patent of Boniva was US7410957, titled 'Method of treatment using bisphosphonic acid', which expires on 2023-05-06. Boniva generic will be available shortly after. Below are the details of the patent: